S. Harrison

发表

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

Joel Z Stengel, Christopher D. Williams, Michael Asike, 2011, Gastroenterology.

TEMPORARY REMOVAL: Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.

K. Cusi, J. Colca, A. Sanyal, 2019, Journal of hepatology.

Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis

Z. Younossi, Donghee Kim, Aijaz Ahmed, 2019, Journal of Gastroenterology.

Authors’ reply

B. Neuschwander‐Tetri, S. Harrison, 2009, Gut.

Nonalcoholic fatty liver disease.

D. Torres, S. Harrison, M. Hjelkrem, 2020, Minerva medica.

Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis

D. Bernstein, Z. Younossi, A. Singal, 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Manifestations of chronic hepatitis C virus infection beyond the liver.

L. Dal Maso, Z. Younossi, P. Cacoub, 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy

J. Albrecht, K. Koury, H. Tillmann, 2010, Hepatology.

Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH

Z. Goodman, A. Feldstein, A. Eguchi, 2020, Hepatology communications.

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12‐month randomized, prospective, open‐ label trial

Christopher D. Williams, D. Torres, J. Shaw, 2011, Hepatology.

Hepatitis C virus: a critical appraisal of approaches to therapy.

T. Hassanein, G. Davis, G. Everson, 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Cognitive Lifetime Drinking History in Nonalcoholic Fatty Liver Disease: Some Cases May Be Alcohol Related

M. Russell, T. Nochajski, P. Hayashi, 2004, American Journal of Gastroenterology.

Noninvasive methods of assessing nonalcoholic fatty liver disease: what the clinician needs to know.

D. Torres, S. Harrison, 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Abnormal liver tests and fatty liver on ultrasound.

S. Harrison, 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patients

D. Helinski, P. Hayashi, S. Harrison, 2004, Alimentary pharmacology & therapeutics.

Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005–2016

Z. Younossi, G. Cholankeril, Donghee Kim, 2019, Hepatology International.

Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease

Christopher D. Williams, S. Harrison, Nadege T Touzin, 2011, Therapeutic advances in gastroenterology.

Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review

N. Terrault, V. Ajmera, S. Harrison, 2017, Hepatology.

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.

D. Rockey, Z. Goodman, J. Bosch, 2018, Gastroenterology.

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

K. Cusi, T. Okanoue, A. Sanyal, 2020, The New England journal of medicine.

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

L. J. Hardies, K. Cusi, A. Gastaldelli, 2009, Hepatology.

Nonalcoholic steatohepatitis: what we know in the new millennium

S. Kadakia, S. Schenker, S. Harrison, 2002, American Journal of Gastroenterology.

Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease.

S. Harrison, W. N. Hannah, 2016, Clinics in liver disease.

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.

M. Connelly, J. Trotter, A. Depaoli, 2019, Journal of hepatology.

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Philippe Lehert, Pierre Bedossa, P. Bedossa, 2016, Gastroenterology.

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

V. Wong, M. Allison, V. Paradis, 2020, The lancet. Gastroenterology & hepatology.

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

V. Wong, F. Tacke, Z. Goodman, 2020, Hepatology.

Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.

K. Cusi, T. Okanoue, A. Sanyal, 2020, Contemporary clinical trials.

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

L. V. Van Gaal, A. Sanyal, S. Calanna, 2019, Alimentary pharmacology & therapeutics.

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

B. Neuschwander‐Tetri, C. Moylan, R. Taub, 2019, The Lancet.

Regenerate: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.

P. Bedossa, Z. Goodman, A. Sanyal, 2019, Contemporary clinical trials.

Pharmacotherapy for NASH: Current and emerging.

M. Konerman, S. Harrison, Jacob C Jones, 2018, Journal of hepatology.

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

V. Wong, F. Tacke, B. Wiens, 2018, Hepatology.

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

B. Neuschwander‐Tetri, G. Marchesini, S. Friedman, 2018, Hepatology.

Overview of Clinical Treatment Trials for NASH

M. Konerman, S. Harrison, 2017, Current Hepatology Reports.

Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)

B. Neuschwander‐Tetri, S. Friedman, N. Chalasani, 2017 .

Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease

S. Harrison, W. N. Hannah, 2016, Digestive Diseases and Sciences.

Hereditary hemochromatosis: update for 2003.

B. Bacon, S. Harrison, 2003, Journal of hepatology.

Current treatments in nonalcoholic steatohepatitis

D. Torres, S. Harrison, 2007, Current treatment options in gastroenterology.

The Pointy End of the NAFLD Iceberg: Cirrhosis, Portal Hypertension, and Liver Failure

D. Torres, S. Harrison, Jonathon W. Schwake, 2013 .

Diabetic hepatosclerosis: diabetic microangiopathy of the liver.

Z. Goodman, E. Brunt, S. Harrison, 2006, Archives of pathology & laboratory medicine.

Orlistat in the Treatment of NASH: A Case Series

B. Bacon, E. Brunt, S. Harrison, 2003, American Journal of Gastroenterology.

Noninvasive Tests (NITs) in the Management of Nonalcoholic Steatohepatitis (NASH)

R. Loomba, S. Harrison, 2020 .

Protein synthesis inhibitors activate glucose transport without increasing plasma membrane glucose transporters in 3T3-L1 adipocytes.

M. Czech, J. Buxton, S. Harrison, 1991, The Journal of biological chemistry.

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.

C. Mantzoros, R. Eckel, K. Cusi, 2021, Gastroenterology.

Current and Emerging Therapies in Nonalcoholic Fatty Liver Disease

D. Torres, S. Harrison, Maryam R. Kashi, 2008, Seminars in liver disease.

Vitamin D and nonalcoholic fatty liver disease (NAFLD): Is it more than just an association?

D. Torres, S. Harrison, R. Kwok, 2013, Hepatology.

Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies

P. Marcellin, K. Reddy, M. Diago, 2012, Expert opinion on drug safety.

New Advances in Evaluation and Management of Patients with Polycystic Liver Disease

S. Harrison, H. Arnold, Hays L. Arnold, 2005, The American Journal of Gastroenterology.

Intensified Peginterferon &agr;-2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein

K. Reddy, M. Shiffman, D. Messinger, 2013, Journal of clinical gastroenterology.

Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.

V. Wong, S. Sarin, Z. Goodman, 2020, Journal of hepatology.

Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways.

Aijaz Ahmed, R. Wong, S. Harrison, 2015, World journal of hepatology.

Depression is associated with non‐alcoholic fatty liver disease among adults in the United States

Andrew A. Li, G. Cholankeril, Donghee Kim, 2019, Alimentary pharmacology & therapeutics.

Costs and consequences: Hepatitis C seroprevalence in the military and its impact on potential screening strategies

Philip J. L. Gould, S. Peel, N. Michael, 2016, Hepatology.

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.

P. Thuluvath, V. Luketic, N. Pyrsopoulos, 2016, Annals of hepatology.

Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection

Tara L. Kieffer, A. Kwong, M. Tausek, 2008 .

Editorial: Killing Two Birds With One Stone: Screening for Chronic Hepatitis C at the Time of Colonoscopy in the Baby Boomer Cohort

D. Torres, S. Harrison, 2013, The American Journal of Gastroenterology.

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.

William M. Lee, J. Albrecht, K. Reddy, 2010, Gastroenterology.

HCV in Patients With End-Stage Renal Disease

J. Simon, S. Harrison, J. Bucci, 2008, The American Journal of Gastroenterology.

Small Molecule and Novel Treatments for Chronic Hepatitis C Virus Infection

S. Harrison, 2007, The American Journal of Gastroenterology.

High prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population?

Aijaz Ahmed, S. Harrison, R. Perumpail, 2016, Hepatology.

Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis

Christopher D. Williams, D. Torres, S. Harrison, 2012, Hepatology.

Non-Alcoholic Steatohepatitis: Effect of Roux-en-Y Gastric Bypass Surgery

S. Harrison, J. Goldberg, S. Bowers, 2006, The American Journal of Gastroenterology.

Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.

B. Neuschwander‐Tetri, B. Bacon, D. Oliver, 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Physical activity: an essential component of lifestyle modification in NAFLD

D. Torres, S. Harrison, B. Rodriguez, 2012, Nature Reviews Gastroenterology &Hepatology.

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

B. Neuschwander‐Tetri, E. Brunt, S. Harrison, 2009, Hepatology.

Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial

Christopher D. Williams, D. Torres, J. Shaw, 2013, Therapeutic advances in gastroenterology.

Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial

S. Neubauer, P. Traber, R. Banerjee, 2018, PloS one.

Nonalcoholic fatty liver disease and elastography: Incremental advances but work still to be done

S. Harrison, W. N. Hannah, William N. Hannah, 2016, Hepatology.

NASH, from diagnosis to treatment: Where do we stand?

S. Harrison, 2015, Hepatology.

H. pylori and platelet counts

S. Harrison, H. Arnold, 2006, Hepatology.

Practice patterns in NAFLD and NASH: real life differs from published guidelines

B. Neuschwander‐Tetri, K. Kowdley, R. Loomba, 2016, Therapeutic advances in gastroenterology.

Liver biopsy versus noninvasive testing in chronic hepatitis C: Where do we stand in 2008?

S. Harrison, John S. Aita, John S Aita, 2008 .

Association of Serum Adipocytokines With Insulin Resistance and Liver Injury in Patients With Chronic Hepatitis C Genotype 4

Mahmoud A. Khattab, S. Harrison, M. Eslam, 2012, Journal of clinical gastroenterology.

Antiviral Therapy for the Management of Hepatitis C

S. Harrison, Christine L. Y. Lee, 2005 .

NAFLD: Predictive value of ALT levels for NASH and advanced fibrosis

D. Torres, S. Harrison, 2013, Nature Reviews Gastroenterology &Hepatology.

NAFLD: Reporting Histologic Findings in Clinical Practice

B. Neuschwander‐Tetri, D. Kleiner, A. Sanyal, 2021, Hepatology.

Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease

S. Harrison, M. Chakravarthy, Z. Younes, 2021, The American journal of gastroenterology.

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

V. Wong, J. Trotter, M. Shiffman, 2020, Hepatology.

Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.

Jennifer M Aldridge Whitehead, S. Neubauer, V. Paradis, 2021, Journal of hepatology.

Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality.

Z. Younossi, G. Cholankeril, Donghee Kim, 2020, The American journal of gastroenterology.

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

B. Neuschwander‐Tetri, G. Marchesini, S. Friedman, 2017, Hepatology.

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

Mahmoud A. Khattab, M. Manns, M. Colombo, 2011, Journal of hepatology.

From NAFLD to MAFLD: Implications of a Premature Change in Terminology

Z. Goodman, A. Sanyal, Z. Younossi, 2020, Hepatology.

The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic

E. Brunt, S. Harrison, D. Battafarano, 2015, Alimentary pharmacology & therapeutics.

Validation of the non‐alcoholic fatty liver disease activity score

J. Shaw, S. Harrison, M. Hjelkrem, 2011, Alimentary pharmacology & therapeutics.

The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial

W. Coyle, S. Harrison, William W Shields, 2009, Therapeutic advances in gastroenterology.

Chapter 28 – Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

D. Torres, S. Harrison, 2010 .

What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?

Monica A. Tincopa, R. Loomba, N. Alkhouri, 2021, Hepatology communications.

Preparing for the NASH epidemic: A call to action

C. Mantzoros, R. Eckel, K. Cusi, 2021, Obesity.

A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes

Liping Liu, S. Harrison, A. D. Di Bisceglie, 2021, Nature Communications.

Preparing for the NASH epidemic: A call to action.

C. Mantzoros, R. Eckel, K. Cusi, 2021, Metabolism: clinical and experimental.

Noninvasive measure of treatment response in non‐alcoholic steatohepatitis: Insights from EMMINENCE and meta‐analysis

G. Koch, H. Dittrich, R. Loomba, 2021, JGH open : an open access journal of gastroenterology and hepatology.

A Phase 2, Randomized Controlled Trial of Berberine Ursodeoxycholate (BUDCA) in Patients with Presumed Non-Alcoholic Steatohepatitis (NASH) and Type 2 Diabetes

A. Bisceglie, Liping Liu, S. Harrison, 2021 .

Preparing for the NASH Epidemic: A Call to Action.

C. Mantzoros, R. Eckel, K. Cusi, 2021, Gastroenterology.

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.

J. Trotter, J. Frias, C. Guy, 2020, Gastroenterology.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Manfred von der Ohe, A. Coates, C. Trautwein, 2019, The Lancet.

Insulin sensitizers in nonalcoholic steatohepatitis

K. Cusi, S. Schenker, S. Harrison, 2011, Hepatology.

Complex regulation of simple sugar transport in insulin-responsive cells.

M. Czech, S. Harrison, A. Pessino, 1992, Trends in biochemical sciences.

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.

P. Thuluvath, M. Kipnes, M. Abdelmalek, 2022, The lancet. Gastroenterology & hepatology.

Early Cardiac Dysfunction in Biopsy-proven Nonalcoholic Fatty Liver Disease.

Peter C Johnson, J. Aden, Rosco S Gore, 2021, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

Nonalcoholic fatty liver disease and fibrosis progression: the good, the bad, and the unknown.

S. Harrison, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

K. Cusi, D. Moller, N. Alkhouri, 2021, The lancet. Gastroenterology & hepatology.

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

B. Neuschwander‐Tetri, G. Gores, J. Wayne, 2021, Gastroenterology.

NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients

J. Trotter, R. Loomba, M. Abdelmalek, 2017 .

Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes

V. Wong, Z. Goodman, M. Stepanova, 2020, Hepatology communications.

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

Z. Goodman, J. Bosch, A. Sanyal, 2019, Hepatology.

Activation of cell surface glucose transporters measured by photoaffinity labeling of insulin-sensitive 3T3-L1 adipocytes.

M. Czech, S. Harrison, A. Pessino, 1992, The Journal of biological chemistry.

Correlation between insulin resistance and hepatitis C viral load

S. Harrison, 2006, Hepatology.

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

T. Rolph, E. Tillman, P. Ruane, 2021, Nature Medicine.

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

V. Wong, Z. Goodman, T. Okanoue, 2021, Hepatology.

MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.

J. Gornbein, Ju Dong Yang, R. Saouaf, 2021, Journal of hepatology.

The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.

M. Karsdal, B. Neuschwander‐Tetri, Z. Goodman, 2021, Contemporary clinical trials.

Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.

M. Stepanova, A. Sanyal, Z. Younossi, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH).

V. Wong, M. Stepanova, M. Trauner, 2020, Gastroenterology.

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.

J. Chan, D. Schuppan, Z. Goodman, 2019, Journal of hepatology.

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

B. Neuschwander‐Tetri, A. Sanyal, R. Loomba, 2018, The Lancet.

qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis

F. Liu, A. Wee, M. Romero-Gómez, 2020, Hepatology.

NGM 282 for treatment of non-alcoholic steatohepatitis : a multicentre , randomised , double-blind , placebo-controlled , phase 2 trial

J. Trotter, M. Jaros, R. Loomba, 2018 .

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

J. Trotter, M. Jaros, R. Loomba, 2018, The Lancet.

Unconjugated hyperbilirubinemia is inversely associated with non‐alcoholic steatohepatitis (NASH)

S. Harrison, M. Hjelkrem, A. Morales, 2012, Alimentary pharmacology & therapeutics.

Hepatic progenitor cells: Another piece in the nonalcoholic fatty liver disease puzzle

D. Torres, S. Harrison, 2012, Hepatology.

Do we need a histological score to diagnose non‐alcoholic steatohepatitis? authors’ reply

S. Harrison, M. Hjelkrem, 2011 .

Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

E. Ravussin, S. Klein, C. Ukomadu, 2022, Nature Medicine.

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.

R. Loomba, M. Noureddin, M. Middleton, 2018, Gastroenterology.

Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis

D. Torres, S. Harrison, 2015, Hepatology.

Nonalcoholic fatty liver disease: is it all in the genes?

D. Torres, S. Harrison, 2010, Hepatology.

The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial)

K. Brown, S. Harrison, D. Labrecque, 2015, Therapeutic advances in gastroenterology.

Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series

N. Chalasani, D. Torres, S. Harrison, 2010, The American Journal of Gastroenterology.

Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases

A. Sanyal, G. Hirschfield, U. Beuers, 2021, JHEP reports : innovation in hepatology.

Graft Outcomes in Kidney Transplantation Alone with Concomitant Cirrhosis

S. Harrison, Anish A. Patel, M. Rudraraju, 2016 .

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

R. Taub, N. Alkhouri, M. Bashir, 2021, Hepatology communications.

Suppressed intrinsic catalytic activity of GLUT1 glucose transporters in insulin-sensitive 3T3-L1 adipocytes.

M. Czech, J. Buxton, S. Harrison, 1991, Proceedings of the National Academy of Sciences of the United States of America.

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

T. Rolph, E. Tillman, P. Ruane, 2022, JHEP reports : innovation in hepatology.

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.

M. Karsdal, J. Trotter, J. Drenth, 2019, Journal of hepatology.

Ela fi branor , an Agonist of the Peroxisome Proliferator L Activated Receptor L a and L d , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

P. Bedossa, J. Drenth, A. Sanyal, 2022 .

Elevated urinary bisphenol A levels are associated with non‐alcoholic fatty liver disease among adults in the United States

Andrew A. Li, G. Cholankeril, Donghee Kim, 2019, Liver international : official journal of the International Association for the Study of the Liver.

55 METABOLIC AND ANTI-INFLAMMATORY BENEFICIAL EFFECTS OF PIOGLITAZONE (PIO) TREATMENT IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND THEIR ASSOCIATIONS WITH HISTOLOGICAL IMPROVEMENT

K. Cusi, A. Gastaldelli, D. Ciociaro, 2009 .

Preparing for the NASH Epidemic: A Call to Action

C. Mantzoros, R. Eckel, K. Cusi, 2021, Diabetes Care.

The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.

Z. Goodman, M. Stepanova, J. Bosch, 2018, Journal of hepatology.

Evidence that erythroid-type glucose transporter intrinsic activity is modulated by cadmium treatment of mouse 3T3-L1 cells.

M. Czech, J. Buxton, S. Harrison, 1991, The Journal of biological chemistry.

Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis

Andrew A. Li, K. Lindor, P. Kwo, 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Maintaining Patient Safety and Data Integrity of Nonalcoholic Steatohepatitis Clinical Trials During the Severe Acute Respiratory Syndrome–Coronavirus 2 Pandemic

R. Loomba, N. Alkhouri, S. Harrison, 2020, Hepatology (Baltimore, Md.).

Maintaining Patient Safety and Data Integrity of NASH Clinical Trials During the SARS-CoV-2 Pandemic.

R. Loomba, N. Alkhouri, S. Harrison, 2020, Hepatology.

Is it time to write a prescription for coffee? Coffee and liver disease.

D. Torres, S. Harrison, 2013, Gastroenterology.

Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018

Shelly C. Lu, V. Wong, Ju Dong Yang, 2022, Hepatology communications.

Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease

P. Bossuyt, M. Nieuwdorp, J. Schattenberg, 2021, Biomedicines.

A new approach to therapy for hepatocellular carcinoma?

S. Harrison, A. D. Di Bisceglie, 2003, Hepatology.

CLINICAL — LIVER Ela ﬁ branor, an Agonist of the Peroxisome Proliferator L Activated Receptor L a and L d , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

P. Bedossa, J. Drenth, A. Sanyal, 2022 .

The role of consensus interferon in the current treatment of chronic hepatitis C viral infection.

T. Hassanein, E. Fish, S. Harrison, 2008, Gastroenterology & hepatology.

Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes

P. Puri, Z. Younossi, G. Cholankeril, 2017, Digestive Diseases and Sciences.

Synthesis of α-substituted vinylsulfonium salts and their application as annulation reagents in the formation of epoxide- and cyclopropane-fused heterocycles.

D. Coe, S. Harrison, V. Aggarwal, 2014, The Journal of organic chemistry.

Evidence that functional erythrocyte-type glucose transporters are oligomers.

D. Hebert, M. Czech, J. Buxton, 1991, The Journal of biological chemistry.

Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.

J. Dufour, Z. Goodman, A. Sanyal, 2021, Journal of hepatology.

Insulin action on activity and cell surface disposition of human HepG2 glucose transporters expressed in Chinese hamster ovary cells.

M. Czech, J. Buxton, S. Harrison, 1990, The Journal of biological chemistry.

Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?

S. Harrison, M. Pavlides, F. Mózes, 2021, Gut.

Nonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges

E. Pham, G. Cholankeril, Aijaz Ahmed, 2016, Hepatology.

Fat and the liver--a molecular overview.

A. Diehl, S. Harrison, 2002, Seminars in gastrointestinal disease.

The times they are a-changin' (for NAFLD as well).

A. Sanyal, U. Beuers, R. Loomba, 2020, Journal of hepatology.

Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis

V. Wong, K. Cusi, Z. Younossi, 2022, Journal of clinical gastroenterology.

Current Treatments in Current Treatments in Nonalcoholic Steatohepatitis Nonalcoholic Steatohepatitis

D. Torres, S. Harrison, 2007 .

Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis.

K. Cusi, A. Gastaldelli, S. Schenker, 2007, Journal of hepatology.

730 NASH: clinical assessment of 501 patients from two separate academic medical centers with validation of a clinical scoring system for advanced hepatic fibrosis

B. Neuschwander‐Tetri, D. Oliver, S. Harrison, 2003 .

Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score

D. Kleiner, M. Valasek, B. Aqel, 2022, Hepatology.

Effect of NGM 282 , a FGF 19 analogue , in Primary Sclerosing Cholangitis : a Multicentre , Randomized , Double-Blind , Placebo-Controlled Phase 2 Trial

M. Karsdal, J. Trotter, J. Drenth, 2018 .

Effect of Weight Loss on Nonalcoholic Fatty Liver Disease

D. Torres, S. Harrison, Anish A. Patel, 2009, Journal of clinical gastroenterology.

Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis

B. Neuschwander‐Tetri, G. Marchesini, S. Friedman, 2017 .

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Michael Charlton, K. Cusi, N. Chalasani, 2018, Hepatology.

Steatosis and chronic hepatitis C infection: mechanisms and significance.

S. Harrison, 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Cardiovascular Disease and Nonalcoholic Fatty Liver Disease: Does Histologic Severity Matter?

S. Harrison, J. Domanski, Stephen J Park, 2012, Journal of clinical gastroenterology.

1161 ASSOCIATION OF SERUM ADIPOCYTOKINES WITH LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4

Mahmoud A. Khattab, S. Harrison, M. Eslam, 2011 .

Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single‐blind, placebo‐controlled study in F2/F3 NASH

D. Ure, S. Harrison, D. Trepanier, 2022, Hepatology communications.

Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.

M. Wolf, A. Sanyal, C. Bureau, 2022, Journal of hepatology.

Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials

M. Noureddin, N. Alkhouri, S. Harrison, 2022, Expert opinion on investigational drugs.

Reply:

B. Neuschwander‐Tetri, E. Brunt, S. Harrison, 2009 .

Prospective prevalence study of adult NAFLD/NASH utilizing multi-modality imaging compared with liver bopsy

V. Paradis, P. Bedossa, J. Aden, 2017 .

Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection

S. Harrison, Christopher J. Calcagno, Brad Q. Starley, 2010, Hepatology.

Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension.

J. Chan, P. Thuluvath, J. Bosch, 2019, Journal of hepatology.

HCV Replication and Statin Pleotropism: An Adjuvant Treatment Panacea?

D. Torres, S. Harrison, 2008, The American Journal of Gastroenterology.

Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States

Z. Younossi, G. Cholankeril, Aijaz Ahmed, 2017, Journal of Clinical and Translational Hepatology.

Lamivudine Monotherapy in Decompensated Cirrhosis Due to HBeAg Negative Chronic HBV Infection

M. Russell, T. Nochajski, P. Hayashi, 2004, American Journal of Gastroenterology.

Treatment of nonalcoholic fatty liver disease: Role of dietary modification and exercise

D. Torres, S. Harrison, A. Paredes, 2012, Clinical liver disease.

Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease

B. Neuschwander‐Tetri, D. Oliver, S. Harrison, 2008, Gut.

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores

V. Wong, V. de Lédinghen, L. Sandrin, 2022, Journal of hepatology.

Nutrition in cirrhosis and chronic liver disease.

D. Torres, S. Harrison, Wassem Y. Juakiem, 2014, Clinics in liver disease.

Nonalcoholic Fatty Liver Disease Presenting With an Isolated Elevated Alkaline Phosphatase

S. Harrison, M. W. Pantsari, 2006, Journal of clinical gastroenterology.

Features, diagnosis, and treatment of nonalcoholic fatty liver disease.

D. Torres, S. Harrison, C. D. Williams, 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Vitamin D and NAFLD : Is it More Than Just an Association ?

D. Torres, S. Harrison, R. Kwok, 2013 .

Structure–function studies on nucleoside antibiotic mureidomycin A: synthesis of 5′-functionalised uridine models

T. Bugg, M. Inukai, S. Harrison, 1999 .

Hepatitis B seroprevalence in the U.S. military and its impact on potential screening strategies

S. Peel, L. Jagodzinski, N. Michael, 2020, Military medicine.

Anemia during treatment with peginterferon Alfa‐2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT‐2) trial

M. Manns, J. Albrecht, K. Koury, 2013, Hepatology.

Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.

P. Woollard, K. Thewlis, S. Ward, 2011, Journal of medicinal chemistry.

Preparation and protonation of [ReBr(N2Ph)2(PPh3)2]. Structure of [ReBr2(NNPh)(NNHPh)(PPh3)2], a complex with a hydrazido(2-) ligand with a large angular distortion

D. Walton, J. Dilworth, S. Harrison, 1985 .

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.

G. Koch, J. Colca, A. Sanyal, 2020, Journal of hepatology.

S. Harrison, P. Shah, R. Patil, 2022, Hepatology.

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis.

L. N. Valenti, K. Clément, M. Karsdal, 2021, Journal of hepatology.

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Robert P. Myers, Ziad Younes, Quentin M. Anstee, 2019, Hepatology.

Liver disease in patients with diabetes mellitus.

S. Harrison, 2006, Journal of clinical gastroenterology.

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis

V. Wong, M. Ziol, V. de Lédinghen, 2021, Gut.

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Aijaz Ahmed, Z. Younossi, Aijaz Ahmed, 2015, Gastroenterology.

Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP‐C trials

D. Torres, S. Harrison, 2013, Hepatology.

Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.

K. Reddy, M. Shiffman, S. Harrison, 2010, Gastroenterology.

Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.

E. Lawitz, D. Torres, S. Harrison, 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Interleukin 28B polymorphisms are the only common genetic variants associated with low‐density lipoprotein cholesterol (LDL‐C) in genotype‐1 chronic hepatitis C and determine the association between LDL‐C and treatment response

K. Shianna, D. Ge, D. Goldstein, 2012, Journal of viral hepatitis.

Impact of obesity on treatment of chronic hepatitis C

M. Charlton, S. Harrison, P. Pockros, 2006, Hepatology.

Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

S. Harrison, W. N. Hannah, William N. Hannah, 2016, Hepatology.

Diagnosis and therapy of nonalcoholic steatohepatitis.

D. Torres, S. Harrison, Stephen A. Harrison, 2008, Gastroenterology.

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension.

H. Conjeevaram, N. Chalasani, D. Rockey, 2019, Gastroenterology.

Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis

L. Ohno-Machado, Jihoon Kim, Z. Goodman, 2022, Scientific Reports.

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

B. Neuschwander‐Tetri, S. Friedman, V. Miller, 2017, Hepatology.

Randomised clinical study: GR‐MD‐02, a galectin‐3 inhibitor, vs. placebo in patients having non‐alcoholic steatohepatitis with advanced fibrosis

B. Neuschwander‐Tetri, N. Chalasani, P. Traber, 2016, Alimentary pharmacology & therapeutics.

NASH and HCC.

S. Harrison, John M. Page, 2009, Clinics in liver disease.

Chronic HCV and Steatosis

D. Torres, S. Harrison, 2012 .

Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention.

B. Bacon, S. Harrison, 2005, The Medical clinics of North America.

Clinical evaluation of a vaccinia‐vectored Hantaan virus vaccine

C. Schmaljohn, S. Harrison, S. Harrison, 2000, Journal of medical virology.

The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.

M. Allison, J. Dufour, F. Betsou, 2020, Contemporary clinical trials.

Syphilitic hepatitis uncommon presentation of an old scourge.

C. Mulder, S. Harrison, Katherine M. Cebe, 2015, Military medicine.

Extrahepatic Manifestations of Hepatitis C

S. Harrison, N. Palekar, 2005, Southern medical journal.

Anemia During Treatment With Peginterferon Alfa-2B/Ribavirin With or Without Boceprevir is Associated With Higher SVR Rates: Analysis of Previously Untreated and Previous-Treatment-Failure Patients

M. Manns, J. Albrecht, M. Burroughs, 2011 .

476 ANEMIA DURING TREATMENT WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN WITH OR WITHOUT BOCEPREVIR IS ASSOCIATED WITH HIGHER SVR RATES: ANALYSIS OF PREVIOUSLY UNTREATED AND PREVIOUS-TREATMENT-FAILURE PATIENTS

M. Manns, J. Albrecht, K. Reddy, 2011 .

Mixed lineage kinase 3 mediates release of C‐X‐C motif ligand 10–bearing chemotactic extracellular vesicles from lipotoxic hepatocytes

G. Gores, H. Malhi, S. Bronk, 2016, Hepatology.

Changing Trends in Etiology‐Based and Ethnicity‐Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States

Andrew A. Li, J. Glenn, Z. Younossi, 2019, Hepatology.

Nonalcoholic fatty liver disease.

D. Torres, S. Harrison, A. Paredes, 2008, Clinics in liver disease.

Inflammatory bowel disease: thinking outside of the intestines (Part 2).

S. Harrison, Jonathan M Ricker, 2008, Journal of the Mississippi State Medical Association.

Hepatitis C virus infection and nonalcoholic steatohepatitis.

S. Harrison, Anish A. Patel, 2012, Gastroenterology & hepatology.

ACR Appropriateness Criteria radiologic management of hepatic malignancy.

Charles E Ray, Ghassan K Abou-Alfa, Michael D Darcy, 2012, Journal of the American College of Radiology : JACR.

An assessment by the Statin Liver Safety Task Force: 2014 update.

N. Chalasani, H. Bays, D. Cohen, 2014, Journal of clinical lipidology.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

J. Hardies, R. DeFronzo, K. Cusi, 2006, The New England journal of medicine.

Predictors of nonalcoholic steatohepatitis and significant fibrosis in non‐obese nonalcoholic fatty liver disease

Z. Younossi, Donghee Kim, Aijaz Ahmed, 2018, Liver international : official journal of the International Association for the Study of the Liver.

New treatments for nonalcoholic fatty liver disease

S. Harrison, 2006, Current gastroenterology reports.

Insulin resistance in chronic hepatitis C, genotypes 1 and 4: The unfortunate reality

D. Torres, S. Harrison, 2008, Hepatology.

A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.

P. Bedossa, A. Sanyal, D. Hum, 2020, The lancet. Gastroenterology & hepatology.

Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease

A. Bisceglie, S. Harrison, 2012, Drugs.

Pharmacologic management of nonalcoholic fatty liver disease.

B. Neuschwander‐Tetri, S. Harrison, 2004, Clinics in liver disease.

Insulin resistance and hepatitis C: an evolving story

Mahmoud A. Khattab, S. Harrison, M. Eslam, 2011, Gut.

The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH

A. Sanyal, R. Loomba, S. Harrison, 2020, Hepatology.

Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.

B. Neuschwander‐Tetri, D. Kleiner, M. Yeh, 2022, Journal of hepatology.

Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.

A. Sanyal, Z. Younossi, R. Loomba, 2021, Gastroenterology.

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

N. Lanthier, P. Bedossa, A. Sanyal, 2021, The New England journal of medicine.

A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.

M. Bashir, E. Lawitz, S. Harrison, 2021, Journal of hepatology.

Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease.

Z. Younossi, G. Cholankeril, Donghee Kim, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis

P. Hayashi, S. Schenker, S. Harrison, 2003, American Journal of Gastroenterology.

Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid

L. Beretta, M. Fallon, G. Ioannou, 2017, PloS one.

Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.

Aijaz Ahmed, Aijaz Ahmed, R. Wong, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease

R. Loomba, S. Harrison, S. Jayakumar, 2016, Current Hepatology Reports.

Olanzapine and benztropine as a cause of ischemic colitis in a 27-year-old man.

S. Harrison, Nadege T. Gunn, Stephen J Park, 2012, Journal of clinical gastroenterology.

Insulin resistance in chronic hepatitis C: the search for effective drug treatment continues

S. Harrison, M. Lincoln, K. Roberts, 2012, Expert review of gastroenterology & hepatology.

Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis.

V. Wong, Z. Goodman, M. Stepanova, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Challenges and opportunities in NASH drug development

A. Allen, M. Noureddin, N. Alkhouri, 2023, Nature Medicine.

Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH

D. Schuppan, S. Harrison, D. Fraser, 2022, Expert opinion on investigational drugs.

A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.

B. Neuschwander‐Tetri, K. Cusi, M. Yuen, 2022, Journal of hepatology.

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis

J. Trotter, R. Banerjee, M. Jaros, 2019, Hepatology.

The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection

K. Shianna, D. Ge, D. Goldstein, 2012, Digestive Diseases and Sciences.

Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment.

S. Harrison, 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Thiazolidinedione therapy for nonalcoholic steatohepatitis: Go, stop, or proceed with caution?

S. Harrison, 2010, Hepatology.

Nonalcoholic fatty liver disease: Reporting histologic findings in clinical practice.

B. Neuschwander‐Tetri, D. Kleiner, A. Sanyal, 2020, Hepatology.

A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis

K. Kowdley, G. Hirschfield, V. Sundaram, 2022, The American journal of gastroenterology.

Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.

D. Torres, S. Harrison, W. N. Hannah, 2016, Gastroenterology & hepatology.

The AST to ALT Ratio: A Pattern Worth Considering

S. Harrison, J. Domanski, 2013, Current Hepatitis Reports.

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.

P. Thuluvath, C. Mcwherter, C. Berg, 2022, Journal of hepatology.

Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study

S. Bergheanu, T. Hassanein, B. Bacon, 2020, Journal of Hepatology.

Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment.

Joel Z Stengel, Stephen A Harrison, S. Harrison, 2006, Gastroenterology & hepatology.

Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?

D. Torres, S. Harrison, F. Cheng, 2014, Journal of viral hepatitis.

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

L. N. Valenti, C. Trautwein, S. Cockell, 2021, JHEP reports : innovation in hepatology.

A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis: A Randomized Placebo-controlled Trial

D. Torres, S. Harrison, A. Morgan, 2009, Journal of clinical gastroenterology.

Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.

P. Bossuyt, M. Allison, J. Dufour, 2023, The lancet. Gastroenterology & hepatology.

Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis

J. Fallowfield, R. Banerjee, A. Sanyal, 2021, Frontiers in Endocrinology.

Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

B. Neuschwander‐Tetri, S. Harrison, Stephen A Harrison, 2020, Clinical Gastroenterology and Hepatology.

Benefits of lifestyle modification in NAFLD

C. Day, S. Harrison, 2007, Gut.

Occurrence of noncirrhotic HCC in NAFLD

D. Torres, S. Harrison, 2016 .

Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease

Steven P. Larson, S. Harrison, Nicole A. Palekar, 2006, Liver international : official journal of the International Association for the Study of the Liver.

Hepatic Fat Reduction Due to Resmetirom in Patients with Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.

M. Stepanova, Z. Younossi, R. Taub, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

NASH Cirrhosis Trials And Major Adverse Liver Outcomes: Big Data Needed.

M. Noureddin, S. Harrison, 2022, Journal of hepatology.

Controversies in the Diagnosis and Management of NAFLD and NASH.

K. Kowdley, R. Loomba, S. Caldwell, 2014, Gastroenterology & hepatology.

Trends in hospitalizations for chronic liver disease‐related liver failure in the United States, 2005‐2014

Andrew A. Li, P. Kwo, Z. Younossi, 2019, Liver international : official journal of the International Association for the Study of the Liver.

Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis

N. Chalasani, Z. Goodman, M. Noureddin, 2023, Alimentary pharmacology & therapeutics.

A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH

A. Khosla, V. Wong, O. Carrasco-Zevallos, 2021, Hepatology.

Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha‐2a plus ribavirin

S. Harrison, F. Hamzeh, J. Vierling, 2012, Hepatology.

Metabolic Syndrome and HCV: Where Do We Stand in 2010?

S. Harrison, P. Lamb, 2010 .

Review article: nonalcoholic fatty liver disease and hepatitis C virus – partners in crime

S. Harrison, J. Blonsky, 2008, Alimentary pharmacology & therapeutics.

Hepatitis C, insulin resistance, and steatosis

D. Torres, S. Harrison, 2007 .

Hepatitis C virus and insulin resistance/diabetes mellitus.

D. Torres, S. Harrison, 2008, Gastroenterology & hepatology.

Obesity, insulin resistance, and HCV: Implications for pathogenesis

S. Harrison, D. Heppner, 2005 .

Nonalcoholic Steatohepatitis and Noncirrhotic Hepatocellular Carcinoma: Fertile Soil

D. Torres, S. Harrison, 2012, Seminars in Liver Disease.

Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease

S. Harrison, Shane J. Mills, Stephen A. Harrison, 2005, Current gastroenterology reports.

The natural history of nonalcoholic fatty liver disease: a clinical histopathological study

P. Hayashi, S. Harrison, Stephen A Harrison, 2003, American Journal of Gastroenterology.

Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores

M. Noureddin, N. Alkhouri, R. Vuppalanchi, 2023, Hepatology communications.

Insulin regulation of hexose transport in mouse 3T3-L1 cells expressing the human HepG2 glucose transporter.

M. Czech, J. Buxton, S. Harrison, 1990, The Journal of biological chemistry.

Clinical utility of MRI biomarkers for identifying NASH patients' high risk of progression: A multi-center pooled data and meta-analysis.

J. Fallowfield, R. Banerjee, A. Nakajima, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

NIS2+™, an optimization of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: a prospective derivation and validation study.

A. Sanyal, D. Hum, B. Staels, 2023, Journal of hepatology.

15 OPEN-LABEL PROSPECTIVE RANDOMIZED 48 WEEK CLINICAL TRIAL: ROSIGLITAZONE VERSUS ROSIGLITAZONE AND METFORMIN (AVANDAMET) VERSUS ROSIGLITAZONE AND LOSARTAN IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)

D. Torres, J. Shaw, S. Harrison, 2011 .

Peroxisome proliferator-activated receptors and hepatitis C virus

Mahmoud A. Khattab, S. Harrison, M. Eslam, 2011, Therapeutic advances in gastroenterology.

Is the FIBROSpect II® index effective for determining the stage of fibrosis in patients with chronic hepatitis C?

S. Harrison, 2008, Nature Clinical Practice Gastroenterology &Hepatology.

56th EASD Annual Meeting of the European Association for the Study of Diabetes

Birman, Y., Ñ., 2020, Diabetologia.

HCV therapy in 2006: down with ALT levels, in with awareness of co-existent metabolic syndrome.

S. Harrison, 2006, Journal of hepatology.

MiraLAX is not as effective as GoLytely in bowel cleansing before screening colonoscopies.

Joel Z Stengel, Mark Liu, S. Harrison, 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Evaluation of PXL065 - Deuterium-Stabilized (R)-Pioglitazone in NASH Patients: a Phase 2 randomized placebo-controlled trial (DESTINY-1).

K. Cusi, P. Bedossa, D. Moller, 2023, Journal of hepatology.

Noninvasive Diagnostic Approach to NASH: Radiological Diagnostics

Monica A. Tincopa, S. Harrison, M. Tincopa, 2020 .

ALT as a non-invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial

P. Bedossa, A. Sanyal, D. Hum, 2016 .

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Holly E. Holmes, D. Mozaffarian, L. Guarente, 2022, Hepatology.

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.

V. Wong, V. de Lédinghen, P. Bossuyt, 2023, The lancet. Gastroenterology & hepatology.

A217 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL

J. Dufour, P. Bedossa, Z. Goodman, 2021 .

Review: Current status of therapy in nonalcoholic fatty liver disease

S. Harrison, Scott McNear, 2009, Therapeutic advances in gastroenterology.

Il28B Genetic Polymorphism Has Genome Wide Significant Associations with Serum Low Density Lipoprotein Levels and Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C (Chc)

William M. Lee, D. Ge, D. Goldstein, 2010 .

Improved Ultrasound Attenuation Measurement Method for the Non-invasive Evaluation of Hepatic Steatosis Using FibroScan.

S. Bensamoun, F. Charleux, L. Sandrin, 2021, Ultrasound in medicine & biology.

Clinical Trial Landscape in NASH.

R. Loomba, M. Noureddin, J. Dubourg, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Management of anemia in patients receiving protease inhibitors.

S. Harrison, 2012, Gastroenterology & hepatology.

Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience

Aijaz Ahmed, R. Wong, S. Harrison, 2015, Digestive Diseases and Sciences.

Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass.

Steven P. Larson, S. Harrison, S. Bowers, 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Impaired Fasting Glucose Is Associated With Lower Rates of Sustained Virologic Response (SVR) in Patients With Genotype 1 Chronic Hepatitis C (CHC): Retrospective Analysis of the IDEAL Study

William M. Lee, J. Albrecht, M. Shiffman, 2010 .

Review of treatment options for nonalcoholic fatty liver disease.

D. Torres, S. Harrison, Richele L Corrado, 2014, The Medical clinics of North America.

A multi-society Delphi consensus statement on new fatty liver disease nomenclature.

V. Wong, J. Lazarus, K. Cusi, 2023, Annals of hepatology.

Trends in Liver Transplantation Multiple Listing Practices Associated With Disparities in Donor Availability: An Endless Pursuit to Implement the Final Rule.

G. Cholankeril, Aijaz Ahmed, C. Esquivel, 2016, Gastroenterology.

PREPARATION AND PROTONATION OF (REBR(N2PH)2(PPH3)2). STRUCTURE OF (REBR2(NNPH)(NNHPH)(PPH3)2), A COMPLEX WITH A HYDRAZIDO(2-) LIGAND WITH A LARGE ANGULAR DISTORTION

D. Walton, J. Dilworth, S. Harrison, 1985 .

Same Day Endoscopy and Percutaneous Liver Biopsy: Safety and Cost-Effectiveness

S. Harrison, J. Cook, 2009, Digestive Diseases and Sciences.

A multi-society Delphi consensus statement on new fatty liver disease nomenclature.

J. Lazarus, K. Cusi, K. Kowdley, 2023, Journal of hepatology.

Title: Case definitions for inclusion and analysis of endpoints in clinical trials for NASH through the lens of regulatory science Authors:

M. Abdelmalek, Q. Anstee, S. Harrison, 2017 .

Nonalcoholic Fatty Liver Disease: Clinical Features, Disease Modifiers, and Natural History

D. Torres, S. Harrison, 2016 .

NAFLD Review : Diagnosis , Treatment and Outcomes ( Title : 42 characters )

Aijaz Ahmed, R. Wong, S. Harrison, 2015 .

A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis

O. Carrasco-Zevallos, D. Rockey, M. Montalto, 2021, Hepatology.

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

B. Neuschwander‐Tetri, S. Harrison, 2004, Clinics in liver disease.

MRI-AST Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death.

J. Gornbein, M. Noureddin, N. Alkhouri, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Z. Goodman, J. Bosch, A. Sanyal, 2017 .

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.

Deepak L. Bhatt, P. Bedossa, K. Kowdley, 2023, The New England journal of medicine.

Continuous CAP algorithm: reduced variability in a prospective cohort

L. Sandrin, C. Fournier, S. Harrison, 2020, Journal of Hepatology.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

J. Dufour, S. Beckebaum, J. Trotter, 2019, Lancet.

Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in non-alcoholic steatohepatitis and primary sclerosing cholangitis patients

M. Karsdal, J. Trotter, G. Hirschfield, 2020, Journal of Hepatology.

Corrigendum to "Pharmacotherapy for NASH: Current and emerging" [J Hepatol 68 (2017) 362-375].

M. Konerman, S. Harrison, Jacob C Jones, 2018, Journal of hepatology.

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy

J. Albrecht, K. Koury, H. Tillmann, 2010, Hepatology.

The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial

W. Coyle, S. Harrison, William W Shields, 2009, Therapeutic advances in gastroenterology.

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

B. Neuschwander‐Tetri, G. Marchesini, S. Friedman, 2017, Hepatology.

Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis.

J. Dufour, J. Trotter, K. Kowdley, 2023, Journal of hepatology.

Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial

D. Torres, J. Shaw, S. Harrison, 2013, Therapeutic advances in gastroenterology.

Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis

D. Torres, S. Harrison, J. Molloy, 2012, Hepatology.

Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

S. Harrison, W. N. Hannah, 2016, Hepatology.

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

V. Wong, J. Lazarus, K. Cusi, 2023, Hepatology.

The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic

E. Brunt, S. Harrison, D. Battafarano, 2015, Alimentary pharmacology & therapeutics.

NASH and HCC.

S. Harrison, John M. Page, 2009, Clinics in liver disease.

Is it time to write a prescription for coffee? Coffee and liver disease.

D. Torres, S. Harrison, 2013, Gastroenterology.

Comparison of Clinical, Biochemical, and Histopathologic Profiles between NAFLD in Asian-Indians and United States Adults

S. Harrison, L. Viswanathan, S. Kar, 2022, Euroasian journal of hepato-gastroenterology.

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

Joel Z Stengel, Michael Asike, D. Torres, 2011, Gastroenterology.

An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.

R. Ehman, J. Ampuero, R. Loomba, 2023, Journal of hepatology.

TEMPORARY REMOVAL: Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.

K. Cusi, J. Colca, A. Sanyal, 2019, Journal of hepatology.

Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study.

B. Neuschwander‐Tetri, Z. Goodman, A. Sanyal, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study.

B. Neuschwander‐Tetri, Z. Goodman, A. Sanyal, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.